Navigation Links
Northwestern University and ACORN Commence National Enrollment for Metastatic Breast Cancer Study
Date:11/12/2007

MEMPHIS, Tenn., Nov. 12 /PRNewswire/ -- Northwestern University announced today that it has begun enrollment for a national clinical research study for women with locally recurrent or metastatic breast cancer. The Northwestern trial will evaluate the efficacy of Nexavar(R) (sorafenib) tablets in combination with the anticancer drug paclitaxel for metastatic breast cancer. Nexavar, an oral multi kinase inhibitor being co-developed by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals is currently approved for the treatment of kidney cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO )

Northwestern University is collaborating with Accelerated Community Oncology Research Network (ACORN), the Contract Research Organization (CRO) for the trial. The University, primarily through the Feinberg School of Medicine, is part of the McGaw Medical Center of Northwestern University. The McGaw Medical Center is a consortium of urban, suburban, specialized, and general hospitals and the University. Chartered in 1966 and honoring the generosity of the late Foster G. and Mary McGaw, the center presents a greater range of clinical and research experiences than individual teaching hospitals are able to provide.

This research study is a double-blind, placebo-controlled randomized phase 2b study that will be conducted at about 50 sites in approximately 20 states. In addition to evaluating the effectiveness of combining the Nexavar and paclitaxel, the study will measure how well participants tolerate the study drug, and how a participant's quality of life is affected.

Dr. William Gradishar, professor of medicine at the Feinberg School of Medicine of Northwestern University, is the principle investigator of the study. "Sorafenib has demonstrated significant antitumor activity as reported in recent pivotal clinical trials. To further characterize the activity of sorafenib, this clinical trial will randomize patients with metastatic breast cancer to receive weekly paclitaxel or the combination of paclitaxel and sorafenib. This trial will determine if an oral multi-kinase inhibitor adds to the clinical benefit derived from chemotherapy alone in patients with metastatic breast cancer."

Dr. Lee Schwartzberg directs all clinical research initiatives and provides clinical oversight and management of ACORN. "Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals and ACORN seek to advance the standards of cancer care by making the most promising molecules available to the broadest demographic population possible. ACORN's network of community oncology practices along with its centralized clinical trial management services helps make that goal possible," remarked Dr. Schwartzberg.

In addition to this clinical trial, researchers are studying Nexavar in pivotal trials in hepatocellular cancer, metastatic melanoma and non-small cell lung cancer.

Northwestern University

Northwestern University combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. It provides students and faculty exceptional opportunities for intellectual, personal, and professional growth in a setting enhanced by the richness of Chicago. Northwestern is recognized both nationally and internationally for the quality of its educational programs at all levels.

Accelerated Community Oncology Research Network, Inc. (ACORN)

The mission of ACORN is to significantly enhance the speed, accuracy, and productivity of conducting clinical research in the community oncology setting. The ACORN Contract Research Organization (CRO) enrolls research sites, provides contract and budgeting services, fosters the accrual of subjects at the site level, collects data and monitors its accuracy, and works seamlessly as an extension of both the sponsoring organization and the participating research sites.

Contact:

Liz Conway

Accelerated Community Oncology Research Network

1770 Kirby Parkway

Suite 400

Memphis, TN 38138

(901) 435-5570

http://www.ACORNresearch.net


'/>"/>
SOURCE Accelerated Community Oncology Research Network
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evanston Northwestern Healthcare Wins Award For Patient Safety
2. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
3. Northwestern Memorial Hospital Completes Move Into Its New Prentice Womens Hospital
4. Northwestern exposing most deadly infectious diseases in 3-D
5. University of Iowa professor identifies new eating disorder
6. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
8. Tulane University to receive $14M for international HIV/AIDS program
9. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
10. Boston University School of Medicine researcher recipient of Memory Ride Grant
11. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: